Breaking News Instant updates and real-time market news.

GILD

Gilead

$72.64

-0.11 (-0.15%)

07:52
10/18/16
10/18
07:52
10/18/16
07:52

Gilead price target lowered to $100 from $122 at Baird

Baird analyst Brian Skorney lowered his price target on Gilead to $100 from $122 as questions about the durability of Hepatitis C sales plague the stock. The analyst sees the sales decline slowing down and stabilizing and so has trimmed his estimates accordingly. Skorney maintains his Outperform rating on Gilead shares.

  • 06

    Nov

  • 11

    Nov

  • 29

    Nov

GILD Gilead
$72.64

-0.11 (-0.15%)

09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.

TODAY'S FREE FLY STORIES

FRGI

Fiesta Restaurant

$25.95

-0.4 (-1.52%)

17:37
02/27/17
02/27
17:37
02/27/17
17:37
Hot Stocks
Fiesta Restaurant suspends sale evaluation process »

For the past four months,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IPWR

Ideal Power

$2.40

-0.03 (-1.23%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Ideal Power reports Q4 EPS (29c), consensus (29c) »

Reports Q4 revenue $400K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

KRA

Kraton Performance

$27.49

0.68 (2.54%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Kraton Performance reports Q4 EPS 29c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

FLGT

Fulgent Genetics

$11.46

0.23 (2.05%)

17:19
02/27/17
02/27
17:19
02/27/17
17:19
Earnings
Fulgent Genetics reports Q4 EPS 6c, consensus 4c »

Reports Q4 revenue $5.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

, FMER

FirstMerit

17:18
02/27/17
02/27
17:18
02/27/17
17:18
Hot Stocks
Old National names Michael Woods principal accounting officer »

Old National Bancorp…

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

FMER

FirstMerit

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$21.06

0.21 (1.01%)

17:17
02/27/17
02/27
17:17
02/27/17
17:17
Syndicate
Breaking Syndicate news story on Wabash »

Wabash files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTH

Anthera

$0.71

0.0142 (2.05%)

17:15
02/27/17
02/27
17:15
02/27/17
17:15
Earnings
Anthera reports Q4 EPS (36c), consensus (41c) »

The company ended the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$122.40

-0.33 (-0.27%)

17:13
02/27/17
02/27
17:13
02/27/17
17:13
Hot Stocks
Johnson & Johnson: DOJ inquires on Olysio, Massachusetts probes non-profit aid »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

ITGR

Integer

$36.95

0.55 (1.51%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
Integer announces Gary Haire joins company as CFO »

Integer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SHLM

A. Schulman

$33.75

0.05 (0.15%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
A. Schulman to open distribution center at Stryker, Ohio plant »

A. Schulman, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

SWX

Southwest Gas

$85.54

0.24 (0.28%)

17:10
02/27/17
02/27
17:10
02/27/17
17:10
Earnings
Southwest Gas reports Q4 EPS $1.37, consensus $1.35 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$34.18

0.98 (2.95%)

17:09
02/27/17
02/27
17:09
02/27/17
17:09
Hot Stocks
Dermira to present data from DRM04, olumacostat glasaretil clinical programs »

Dermira announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:08
02/27/17
02/27
17:08
02/27/17
17:08
Earnings
Albemarle sees FY17 adjusted EPS $4.00-$4.25, consensus $4.07 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
Albemarle reports Q4 adjusted cont ops EPS 78c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

RAIL

FreightCar America

$14.60

-0.04 (-0.27%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
FreightCar America reports Q4 EPS 1c, consensus 14c »

Reports Q4 revenue $…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:05
02/27/17
02/27
17:05
02/27/17
17:05
Earnings
ZTO Express sees Q1 revenue $360M-$374.4M, consensus $380.54M »

Representing a 27.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:03
02/27/17
02/27
17:03
02/27/17
17:03
Earnings
ZTO Express reports Q4 EPS 15c, consensus 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WUBA

58.com

$32.49

0.52 (1.63%)

17:02
02/27/17
02/27
17:02
02/27/17
17:02
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLAD

Gladstone Capital

$9.22

0.1 (1.10%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Hot Stocks
Gladstone Capital announces investment in unified communications business »

Gladstone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.49

0.52 (1.63%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Earnings
58.com reports Q4 adjusted EPS 0c, consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PRGO

Perrigo

$84.68

0.25 (0.30%)

16:57
02/27/17
02/27
16:57
02/27/17
16:57
Hot Stocks
Perrigo down 11% after results, FY17 guidance, CFO change »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 21

    Mar

STZ

Constellation Brands

$157.80

-1.05 (-0.66%)

16:56
02/27/17
02/27
16:56
02/27/17
16:56
Hot Stocks
Breaking Hot Stocks news story on Constellation Brands »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Earnings
Breaking Earnings news story on AppFolio »

AppFolio sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

RDN

Radian Group

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Syndicate
Breaking Syndicate news story on Radian Group »

Radian Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:54
02/27/17
02/27
16:54
02/27/17
16:54
Earnings
AppFolio reports Q4 EPS (4c), consensus (7c) »

Reports Q4 revenue $28M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.